2026年5月14日，潘普洛纳生物科技（深圳）有限公司（简称“潘普洛纳生物”）宣布，公司基于自主搭建的ASTRIDE®AI平台从头设计开发的首款First-in-Class靶向蛋白降解剂PAM-194，其I期临床研究项目启动会在上海复旦大学附属华山医院顺利召开。

近日，潘普洛纳生物收到国家药品监督管理局药品审评中心（CDE）核准签发的《药物临床试验批准通知书》，其AI平台ASTRIDE®从头设计的首款First-in-Class靶向蛋白降解剂分子即将开展临床试验。

Pamplona Therapeutics and Coherent Biopharma today announced a strategic collaboration to combine Pamplona's AI-driven targeted protein degradation (TPD) molecular design capabilities with Coherent's dual-target conjugation technologies, Bi-XDC and C-PROTAC.

Pamplona Therapeutics today announced that its first-in-class targeted protein degrader for the treatment of autoimmune diseases has received clearance from the U.S. Food and Drug Administration (FDA).